Ioflupane i 123
Celsunax, DaTscan, Ioflupane I (ioflupane i 123) is a small molecule pharmaceutical. Ioflupane i 123 was first approved as Datscan on 2011-01-14. It has been approved in Europe to treat dementia, movement disorders, and radionuclide imaging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| diagnosis | D003933 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| datscan | New Drug Application | 2024-01-10 |
| ioflupane i 123 | ANDA | 2022-12-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinsonian disorders | D020734 | — | G20.C | — | — | 2 | 2 | 5 | 9 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | 1 | 4 | — | 1 | 1 | 6 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 4 | — | 1 | 1 | 6 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 1 | 2 | 1 | 3 | 6 |
| Syndrome | D013577 | — | — | — | — | 2 | 1 | — | 3 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | — | 1 | 1 | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 8 | 4 | — | 25 | 38 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | 1 | 2 | — | 5 | 7 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | 2 | — | 2 | 6 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | — | 2 | — | 1 | 3 |
| Tremor | D014202 | — | R25.1 | — | — | 2 | — | 1 | 3 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | 1 | 2 | — | 1 | 3 |
| Multiple system atrophy | D019578 | — | — | — | 1 | 2 | — | 1 | 3 |
| Atrophy | D001284 | — | — | — | 1 | 2 | — | 1 | 3 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | 1 | — | 1 | — | — | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 1 | — | — | — | 4 |
| Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 3 | — | — | — | 3 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Spinocerebellar degenerations | D013132 | — | G11 | — | — | — | — | 1 | 1 |
| Spinocerebellar ataxias | D020754 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | — | — | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Traumatic stress disorders | D040921 | — | — | — | — | — | — | 1 | 1 |
| Aphasia | D001037 | — | R47.01 | — | — | — | — | 1 | 1 |
| Frontotemporal dementia | D057180 | — | G31.0 | — | — | — | — | 1 | 1 |
| Broca aphasia | D001039 | — | — | — | — | — | — | 1 | 1 |
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ioflupane i 123 |
| INN | ioflupane (123i) |
| Description | Ioflupane I(123) is an azabicycloalkane that is ecgonine methyl ester in which the N-methyl group is replaced by 3-fluoropropyl and the 3beta-hydroxy group is replaced by 4-((123)I)iodophenyl. Used for the imaging of dopamine transporters in the brain of adult patients with potential Parkinsonian Syndromes. It has a role as a radioactive imaging agent and a radiopharmaceutical. It is an azabicycloalkane, an organofluorine compound and a methyl ester. It is functionally related to an ecgonine. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H]1[C@@H](c2ccc([123I])cc2)C[C@@H]2CC[C@H]1N2CCCF |
Identifiers
| PDB | — |
| CAS-ID | 155798-07-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989517 |
| ChEBI ID | — |
| PubChem CID | 3086674 |
| DrugBank | DB08824 |
| UNII ID | 3MM99T8R5Q (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,611 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
477 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use